Mouse PAI-1 Monoclonal Antibody | anti-PAI-1 antibody

PAI-1, Human, mAb MA-33H1F7

Cat. Num. AAA584097

• Gene Names: SERPINE1; PAI; PAI1; PAI-1; PLANH1
• Reactivity: Reactivity: Human. Cross reactivity: Mouse, Rabbit, Rat
• Applications: Western Blot
• Synonyms: PAI-1; Monoclonal Antibody; Human; mAb MA-33H1F7; endothelial plasminogen activator inhibitor; serpin E1; anti-PAI-1 antibody

• Host: Mouse
• Reactivity: Reactivity: Human. Cross reactivity: Mouse, Rabbit, Rat
• Clonality: Monoclonal
• Isotype: Mouse IgG1
• Form/Format: 1 ml (100 ug/ml) 0.2 um filtered antibody solution in PBS, containing 0.1% bovine serum albumin.; For unit size 0.5 mg or larger: PBS only (concentration< 0.5mg/ml)
• Sequence Length: 402

• Applicable Applications for anti-PAI-1 antibody: FS, Immunoassay (IA), Western Blot (WB)
• Application Notes: Application Notes: W: A non-reduced sample treatment and SDS-Page was used. The band size is 52 kDa (Ref.5).; Application Use: For Western blotting, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, dilutions have to be optimized in user's experimental setting.
• Immunogen: Human PAI-1/t-PA complex
• Preparation and Storage: Product should be stored at 4 degree C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.

Related Product Information for anti-PAI-1 antibody

Product Description: Plasminogen activator inhibitor type-1 (PAI-1), a member of the serine protease inhibitor (serpin) superfamily, is an important protein in the regulation of fibrinolysis. PAI-1 is unique among the serpins because of its functional and conformational flexibility. PAI-1 is the most important physiological inhibitor of both tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u- PA). Increased PAI-1 levels are associated with thrombotic events and is an established risk factor for cardiovascular diseases. The active conformation PAI-1 inhibits its target proteinases by the formation of a stable, inactive complex. Although PAI-1 is synthesized as an active molecule, it converts spontaneously to an inactive, latent form that can be partially reactivated by denaturing agents. In addition, a third conformation reacting as a non-inhibitory substrate towards various target proteinases has been identified.
The epitope of monoclonal antibody MA-33H1F7 is predominantly composed of three residues (Lys154/Glu130/Arg131), positioned virtually linearly in the three-dimensional structure. The epitope of the antibody does not cover the complete alpha-helix F and turn connecting alpha-helix F and beta-strand s3A, but is restricted to the hinge region between alpha-helix F and the main part of the PAI-1 molecule.
The monoclonal antibody MA-33H1F7 is a ˜switching antibody, capable of inducing a non-inhibitory substrate form of PAI-1. It was shown to inhibit PAI-1 in a dose dependent manner.

References

1. Debrock, S et al; Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms. Biochim Biophys Acta 1997, 1337: 257 2. Berry, C et al; Antithrombotic activity of a monoclonal antibody inducing the substrate form of plasminogen activator inhibitor type 1 in rat models of venous and arterial thrombosis. Br J Pharm 1998, 125: 29
3. Bijnens, A et al; Importance of the hinge region between alpha-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies. J Biol Chem 2000, 275: 6375
4. Rupin, A et al; Inactivation of plasminogen activator inhibitor-1 accelerates thrombolysis of a platelet-rich thrombus in rat mesenteric arterioles. Thromb Haemst 2001, 86: 1528
5. Sironi, L et al; Effect of valsartan on angiotensin ll-induced plasminogen activator inhibitor-1 biosynthesis in arterial smooth muscle cells. J Am Heart Ass 2001, 37: 961
6. Komissarov, A et al; Redirection of the reaction between activated protein C and a serpin to the substrate pathway. Thromb Res. 2008, 122: 397

NCBI and Uniprot Product Information

• NCBI GI #: 10835159
• NCBI GeneID: 5054
• NCBI Accession #: NP_000593.1
• NCBI GenBank Nucleotide #: NM_000602.4
• Molecular Weight: 43,404 Da
• NCBI Official Full Name: plasminogen activator inhibitor 1
• NCBI Official Synonym Full Names: serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1
• NCBI Official Symbol: SERPINE1
• NCBI Official Synonym Symbols: PAI; PAI1; PAI-1; PLANH1
• NCBI Protein Information: plasminogen activator inhibitor 1; serpin E1; endothelial plasminogen activator inhibitor; serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1
• UniProt Protein Name: Plasminogen activator inhibitor 1
• UniProt Gene Name: SERPINE1
• UniProt Synonym Gene Names: PAI1; PLANH1; PAI; PAI-1
• UniProt Entry Name: PAI1_HUMAN

NCBI Description

This gene encodes a member of the serine proteinase inhibitor (serpin) superfamily. This member is the principal inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA), and hence is an inhibitor of fibrinolysis. Defects in this gene are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency), and high concentrations of the gene product are associated with thrombophilia. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2009]

Uniprot Description

SERPINE1: a secreted protein that acts as 'bait' for tissue plasminogen activator, urokinase, and protein C. Its rapid interaction with TPA may function as a major control point in the regulation of fibrinolysis. Belongs to the serpin family. Interacts with VTN. Binds LRP1B; binding is followed by internalization and degradation. Plasma levels of PAI-1 and VCAM-1 together may be useful in predicting post-operative recurrence in patients with colorectal cancer.

Protein type: Secreted; Motility/polarity/chemotaxis; Secreted, signal peptide

Chromosomal Location of Human Ortholog: 7q22.1

Cellular Component: extracellular matrix; extracellular space; extracellular region; plasma membrane

Molecular Function: serine-type endopeptidase inhibitor activity; protein binding; protease binding; receptor binding

Biological Process: circadian rhythm; extracellular matrix organization and biogenesis; positive regulation of blood coagulation; negative regulation of smooth muscle cell migration; defense response to Gram-negative bacterium; positive regulation of receptor-mediated endocytosis; positive regulation of interleukin-8 production; negative regulation of fibrinolysis; platelet degranulation; transforming growth factor beta receptor signaling pathway; regulation of receptor activity; angiogenesis; chronological cell aging; negative regulation of cell migration; negative regulation of cell adhesion mediated by integrin; transcription initiation from RNA polymerase II promoter; platelet activation; transcription, DNA-dependent; negative regulation of blood coagulation; regulation of cell proliferation; fibrinolysis; positive regulation of angiogenesis; positive regulation of transcription from RNA polymerase II promoter; gene expression; blood coagulation; positive regulation of inflammatory response

Disease: Plasminogen Activator Inhibitor-1 Deficiency